EUROFINS SCIENTIFIC

Eurofins Scientific SE’s latest quarter shows boosted biopharma services, global lab reach, and strategic mergers—fueling growth and investor confidence in the Life Sciences market.

Eurofins Scientific’s 2026 earnings hit €3.7 bn revenue, €1.64 EPS and a share‑repurchase push amid weak organic growth, showing strategic focus on shareholder value.